This suggests that although cancer CNS nurses have some understanding of the use of targeted therapies in their day-to-day practice, but they do not have a clear comprehension of the basis of hereditary cancer treatments for example BRCA1/2-related cancers or hereditary non-polyposis colorectal cancer (HNPCC, also known as Lynch syndrome) (Iyevleva and Imyanitov, 2016). This evidence concerns the gene BRCA1 and Lynch syndrome.